AstraZeneca PLC is a global biopharmaceutical powerhouse and China's largest multinational pharmaceutical company by prescription drug revenue. Founded in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, the company is dual-headquartered in Cambridge, United Kingdom and Södertälje, Sweden, with FY2025 revenue of $58.74 billion (up 21% at CER) and operating profit of $14.4 billion — making it one of the fastest-growing major pharmaceutical companies globally. AstraZeneca employs approximately 80,000 people worldwide, listed on LSE, NASDAQ Stockholm, and NYSE (AZN). The company's growth has been driven by a remarkable strategic pivot from primary care toward oncology, cardiovascular-renal-metabolic (CVRM), respiratory, and rare diseases, with blockbuster drugs like Tagrisso, Imfinzi, Farxiga, and Calquence forming the foundation of a projected $80 billion revenue target by 2030.
Core Business
AstraZeneca's therapeutic portfolio spans five core areas: Oncology (37% of revenue) — anchored by Tagrisso (osimertinib, $7.4B sales), Imfinzi (durvalumab), Lynparza, and Calquence, representing one of the industry's most concentrated oncology franchises; Cardiovascular-Renal-Metabolic (CVRM, 22%) — led by Farxiga (dapagliflozin, $8.0B sales), a market-leading SGLT2 inhibitor with indications spanning diabetes, heart failure, and chronic kidney disease; Respiratory & Immunology (15%) — driven by Symbicort, Breztri, and Fasenra for severe asthma; Rare Disease (13%) — acquired through the $39 billion Alexion merger including Soliris and Ultomiris for complement-mediated disorders; and Vaccines & Immune Therapies (8%) — including the COVID-19 vaccine Vaxzevria and the RSV antibody Beyfortus. The company's R&D expenditure was approximately $14.3 billion in 2025, positioning it among the top 5 global pharmaceutical R&D spenders.
Global Presence
AstraZeneca's manufacturing and commercial footprint spans over 100 countries with 30+ manufacturing sites across 18 countries. China represents AstraZeneca's single most important geographic narrative: mainland China generated $7.3 billion in revenue (approximately 12% of global sales) and the company operates an R&D center, three manufacturing sites, and an AI-driven healthcare innovation hub in the country. In 2025, AstraZeneca announced a landmark separate listing plan for its China business on the Hong Kong Stock Exchange — an unprecedented move by a Western pharmaceutical company that signals the strategic importance of the Chinese market. The company's major manufacturing operations span Sweden (Södertälje — biologics), the UK (Macclesfield, Speke — small molecule and vaccines), the US (Gaithersburg, Frederick — biologics and cell therapy), and China (Wuxi, Taizhou — small molecule and packaging), with a cumulative global small-molecule manufacturing capacity exceeding 10 billion tablets annually.
Key Strengths
Pipeline-Driven Growth Trajectory — AstraZeneca's late-stage pipeline (20+ NMEs in Phase III) supports the company's $80 billion 2030 revenue ambition, with particular strength in antibody-drug conjugates (ADCs) and bispecific antibodies. Oncology Franchise Dominance — the combination of Tagrisso (EGFR-mutant NSCLC standard of care), Imfinzi, and Enhertu creates a durable oncology moat that is difficult for competitors to replicate. China First-Mover Advantage — no other Western pharmaceutical company has matched AstraZeneca's manufacturing investment, R&D localization, and commercial infrastructure depth in China. Portfolio Diversification — the company's balanced presence across oncology, CVRM, respiratory, and rare diseases provides revenue resilience that pure-play oncology or rare disease companies lack. Alexion Integration — the rare disease unit provides high-margin, low-competition revenue streams with Soliris/Ultomiris franchise generating over $7 billion annually. VerityRank Score of 91/100
